Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results